Biotechnology company VistaGen Therapeutics is blazing trails with advances in pluripotent stem cell technology, operating on the belief that “Better Cells Make Better Medicine.” Human Clinical Trials in a Test Tube is the company’s versatile human pluripotent stem cell (hPSC) … Continue reading →

VistaGen Therapeutics, a California-based biotechnology company, is addressing the need to bring effective treatments to market while reducing the time and cost traditionally needed to do so. By leveraging its Human Clinical Trials in a Test Tube™, the company is … Continue reading →

With diseases such as Alzheimer’s, type 2 diabetes, and rheumatoid arthritis on the rise, there is a growing need for new and more effective treatments. But as an editorial by the Washington Post on new drug development initiatives by the … Continue reading →

The U.S. Food and Drug Administration has a low tolerance for drug candidates with safety risks; countless potential new drugs candidates fail in preclinical or clinical trials due to safety concerns, costing pharmaceutical companies billions of dollars in research and … Continue reading →

VistaGen Therapeutics is a California-based biotechnology company that specializes in the application of human pluripotent stem cell (hPSC) technology for drug rescue, including predictive toxicology and drug metabolism screening. The company’s hPSC technology platform, Human Clinical Trials in a Test … Continue reading →

In calendar year 2013, the U.S. FDA’s Center for Drug Evaluation and Research (CDER) approved 27 novel new medicines (NMEs) approved under New Drug Applications (NDAs) and Biologics License Applications (BLAs). This comes from a report from the FDA that … Continue reading →

There’s a pivotal shift taking place the pharmaceutical industry, one that bridges the gap between the company with an $80 billion market cap and heavy cash flow and the one with an $8 million market cap scraping the bottom of … Continue reading →

The U.S. pharmaceutical industry is facing a “drug discovery and development crisis,” says small-cap biotech VistaGen Therapeutics, evidenced by the fact that while the pharmaceutical industry in 2012 invested nearly $49 billion in R&D, a total of only 39 novel … Continue reading →

Human Clinical Trials in a Test Tube™ — sounds like something out of a science fiction movie, but as it turns out, this is science reality. VistaGen Therapeutics is the developer of this versatile human pluripotent stem cell (hPSC) technology … Continue reading →

Each year, the U.S. pharmaceutical industry invests billions of dollars in research and development of novel drugs, but many drugs never reach the final stage of FDA approval. For the pharmaceutical companies engaging in the R&D efforts, that results in … Continue reading →